Published in Liver Int on May 21, 2010
Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.88
Acute abdomen secondary to incarcerated umbilical hernia after treatment of massive cirrhotic ascites. Case Reports Hepatol (2013) 0.88
Albumin reduces paracentesis-induced circulatory dysfunction and reduces death and renal impairment among patients with cirrhosis and infection: a systematic review and meta-analysis. Biomed Res Int (2013) 0.82
TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol (2014) 0.81
Renal dysfunction in cirrhosis is not just a vasomotor nephropathy. Kidney Int (2014) 0.79
Effects of paracentesis on hemodynamic parameters and respiratory function in critically ill patients. BMC Gastroenterol (2014) 0.79
Prevalence of renal dysfunction in patients with cirrhosis according to ADQI-IAC working party proposal. Clin Mol Hepatol (2014) 0.78
Do vasopressin V2 receptor antagonists benefit cirrhotics with refractory ascites? World J Gastroenterol (2015) 0.78
NT-proBNP Changes in Patients with Ascites during Large Volume Paracentesis. ISRN Hepatol (2013) 0.75
Refractory ascites: can it be defined only by the response to furosemide and spironolactone? Liver Int (2010) 0.75
Oral furosemide-induced natriuresis: a potential method for identifying cirrhotic patients with refractory ascites. Liver Int (2010) 0.75
Comprehensive review of post-liver resection surgical complications and a new universal classification and grading system. World J Hepatol (2014) 0.75
Automated low flow pump system for the treatment of refractory ascites: a single-center experience. Langenbecks Arch Surg (2015) 0.75
The Palliative Management of Refractory Cirrhotic Ascites Using the PleurX (©) Catheter. Can J Gastroenterol Hepatol (2016) 0.75
Efficacy of peritoneovenous shunt for treating tolvaptan-resistant refractory ascites in a cirrhotic patient with portal vein thrombosis: A case report. Oncol Lett (2016) 0.75
Acute renal injury after partial hepatectomy. World J Hepatol (2016) 0.75
Management of cirrhotic ascites. Ther Adv Chronic Dis (2015) 0.75
Clinical Features of Refractory Ascites in Outpatients. Clinics (Sao Paulo) (2017) 0.75
Diastolic dysfunction in cirrhosis. Heart Fail Rev (2016) 0.75
Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf) (2017) 0.75
Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology (2010) 8.11
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol (2005) 6.22
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology (2013) 5.88
Vascular disorders of the liver. Hepatology (2009) 5.38
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut (2007) 4.51
Evaluation of the Acute Kidney Injury Network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol (2013) 4.24
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
How to improve care in outpatients with cirrhosis and ascites: a new model of care coordination by consultant hepatologists. J Hepatol (2013) 3.75
Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis. Hepatology (2007) 3.75
Acute-on chronic liver failure. J Hepatol (2012) 3.74
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology (2010) 3.53
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Bacterial translocation (BT) in cirrhosis. Hepatology (2005) 3.07
The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology (2003) 3.00
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology (2010) 2.81
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut (2011) 2.65
Beta-blockers cause paracentesis-induced circulatory dysfunction in patients with cirrhosis and refractory ascites: a cross-over study. J Hepatol (2011) 2.59
Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology (2003) 2.57
Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis (2008) 2.47
Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study. Hepatology (2003) 2.43
Severe sepsis in cirrhosis. Hepatology (2009) 2.33
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology (2010) 2.32
Biased incorporation of ribonucleotides on the mitochondrial L-strand accounts for apparent strand-asymmetric DNA replication. Cell (2002) 2.32
Acute kidney injury in decompensated cirrhosis. Gut (2012) 2.29
Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis. Liver Int (2009) 2.27
Hip pain and heart failure: the missing link. Can J Cardiol (2013) 2.26
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver Int (2014) 2.23
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Liver transplantation for patients with alcoholic liver disease: an open question. Dig Liver Dis (2011) 2.14
Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. J Hepatol (2008) 2.14
The evaluation of renal function and disease in patients with cirrhosis. J Hepatol (2010) 2.10
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int (2008) 2.10
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08
Autophagy in liver diseases. J Hepatol (2010) 2.06
Barcelona Clinic Liver Cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol (2011) 2.04
Association of AKI with mortality and complications in hospitalized patients with cirrhosis. Hepatology (2012) 2.01
Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol (2002) 2.01
Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol (2012) 2.00
Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology (2006) 1.95
Cirrhotic patients in the medical intensive care unit: early prognosis and long-term survival. Crit Care Med (2010) 1.94
Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology (2014) 1.89
The North American Study for the Treatment of Refractory Ascites. Gastroenterology (2003) 1.87
Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol (2002) 1.85
Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. Am J Gastroenterol (2004) 1.83
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Microbial epidemiology and outcome of bloodstream infections in liver transplant recipients: an analysis of 259 episodes. Liver Transpl (2010) 1.81
Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology (2014) 1.81
Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol (2011) 1.79
Recommendations for probiotic use--2008. J Clin Gastroenterol (2008) 1.76
The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int (2009) 1.76
Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience. Hepatology (2012) 1.74
Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology (2006) 1.71
Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology (2008) 1.70
Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol (2010) 1.70
Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis. Gastroenterology (2012) 1.69
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med (2006) 1.67
The hepatic apelin system: a new therapeutic target for liver disease. Hepatology (2008) 1.67
Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation-reperfusion injury. J Hepatol (2004) 1.67
Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases. Kidney Int (2011) 1.64
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology (2013) 1.63
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Serum B-type natriuretic peptide in the initial workup of patients with new onset ascites: a diagnostic accuracy study. Hepatology (2014) 1.60
Hepatitis C: a review for primary care physicians. CMAJ (2006) 1.60
Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 1.60
QT interval prolongation by acute gastrointestinal bleeding in patients with cirrhosis. Liver Int (2012) 1.56
Identification of restricted subsets of mature microRNA abnormally expressed in inactive colonic mucosa of patients with inflammatory bowel disease. PLoS One (2010) 1.54
Intensive care of the patient with cirrhosis. Hepatology (2011) 1.54
The survival benefit of liver transplantation in hepatocellular carcinoma patients. Dig Liver Dis (2010) 1.53
Histological-hemodynamic correlation in cirrhosis-a histological classification of the severity of cirrhosis. J Hepatol (2005) 1.51
High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology (2007) 1.50
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial. Liver Transpl (2002) 1.50
Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology (2007) 1.48
The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem (2008) 1.47
Needle tract seeding after radiofrequency ablation of hepatic tumors. J Vasc Interv Radiol (2005) 1.47
A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology (2004) 1.47
Cognitive impairment and electroencephalographic alterations before and after liver transplantation: what is reversible? Liver Transpl (2014) 1.46
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study. J Clin Gastroenterol (2010) 1.45
Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut (2010) 1.44
Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1. Liver Transpl (2011) 1.44
Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am J Gastroenterol (2004) 1.43
Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology (2003) 1.42
Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology (2011) 1.42
In vivo hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. J Pathol (2010) 1.41
What is behind the presence of anti-neutrophil cytoplasmatic antibodies in chronic liver disease? Liver Int (2009) 1.39
Journals' impact and pecking order: tyranny and tyrannosaurs. Liver Int (2012) 1.39